Investigating type 1 diabetes pathogenesis using the live pancreas tissue slice platform
使用活体胰腺组织切片平台研究 1 型糖尿病发病机制
基本信息
- 批准号:10620116
- 负责人:
- 金额:$ 4.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-16 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:Academic Medical CentersAdoptive TransferAge YearsAntigensAutoantibodiesAutoimmune DiseasesAutoimmune ResponsesAutoimmunityBeta CellC-PeptideCell CommunicationCell DeathCell SurvivalCell physiologyCellsCessation of lifeComplementConfocal MicroscopyCoupledDataDevelopmentDiabetes MellitusDiagnosisDiseaseDisease ProgressionEnvironmentEnzyme-Linked Immunosorbent AssayEventFunctional disorderFutureGene ExpressionGenerationsGlucoseGoalsHumanImmuneImmune mediated destructionImmune systemIn SituInbred NOD MiceIncidenceIndividualInfiltrationInsulinInsulin-Dependent Diabetes MellitusInvestigationKineticsMHC Class I GenesMediatingMitochondriaModelingMonitorMusOnset of illnessOrgan DonorPancreasPathogenesisPathologyPathway interactionsPatientsPharmaceutical PreparationsPlayPopulationPrincipal InvestigatorProcessProductionResearchResearch PersonnelRoleSamplingScientistSliceSplenocyteStressStructure of beta Cell of isletT-LymphocyteTechniquesTestingTimeTissue DonorsTissuesTrainingUnited StatesWorkautoreactive T cellclinical diagnosisdiabetes pathogenesisexperimental studyglucose metabolismglucose tolerancehuman tissueimmune cell infiltrateinflammatory milieuinsulin dependent diabetes mellitus onsetinsulitisisletmouse modelnon-diabeticpreservationpreventprotein expressionresponsesuccesstherapeutic targettherapy designtimeline
项目摘要
Type 1 diabetes (T1D) is an autoimmune disease that results in the destruction of the insulin-producing β cells
of the pancreas. The timeline of T1D development and progression is heterogenous with diagnosis occuring at
a few years of age in some patients versus other patients having autoantibodies for years before diagnosis. In
T1D, immune dysregulation occurs leading to autoantibody production, immune cell infiltration into the islets
(insulitis), and eventual loss of β cells. The events that occur within the β cell during this time and the resulting
impacts on β cell function remain unknown. The goal of this proposal is to determine how β cells function
during the course of T1D development, particularly during the critical early, asymptomatic stages.
Understanding these functional changes within β cells or islets is critical for a complete understanding of
disease progression and for the identification of possible therapeutic targets. The overall objective of my
proposal is to use live pancreas tissue slices to explore how β cells function during T1D development,
specifically I will identify the role immune cell infiltration plays in β cell dysfunction and loss. Live pancreas
tissue slices are ideal for these studies because these samples keep the islet in its native microenvironment
and preserve the extant tissue pathologies, allowing for studies of both β cell function and immune cell
populations. I hypothesize that immune dysregulation early in T1D progression results in dysfunction of the β
cell glucose metabolism pathway primarily mediated by mitochondrial stress, resulting in MHC class I
hyperexpression and increased β cell visibility to the immune system. To test this hypothesis, live pancreas
tissue slices generated from human organ donor tissue will be used and complemented by slices made from
pancreata of mouse models of T1D. Confocal microscopy techniques will be used to determine the degree of
insulitis within the tissue while islet function is simultaneously assessed. Additional functional assessments
such as perifusion experiments followed by insulin ELISAs and gene expression will be employed to look at
function in greater detail. The first part of this proposal focuses on assessments conducted to determine the
impacts of in situ immune cells on β cell function. To gain more control over the disease timeline, particularly to
investigate the earliest stages of disease, HLA-matched T cell avatars will be introduced to control human
pancreas tissue slices, creating an insulitic environment. Disease initiation and progression will be studied
further through adoptive transfer experiments with splenocytes from NOD mouse models. Progression to T1D
will be monitored with live pancreas tissue slices being made as disease develops. Functionality assessments
and immune cell studies will be conducted as discussed above. I expect the contribution of the proposed
research will be the identification of the role that immune dysregulation plays in β cell dysfunction as well as
the mechanistic origination of β cell dysfunction. This will provide critical information about how T1D develops
and will indicate possible therapeutic targets to halt disease progression.
1型糖尿病(T1D)是一种自身免疫性疾病,导致产生胰岛素的β细胞被破坏
胰腺的组织。T1D的发展和进展的时间线是不同的,诊断发生在
一些患者的年龄为几岁,而另一些患者在确诊前已有数年的自身抗体。在……里面
T1D时,发生免疫失调,导致自身抗体产生,免疫细胞渗入胰岛
(胰腺炎),并最终失去β细胞。在这段时间内在β单元格内发生的事件以及由此产生的
对β细胞功能的影响尚不清楚。这项提案的目标是确定β细胞的功能
在T1D发育过程中,特别是在关键的早期无症状阶段。
了解β细胞或胰岛内的这些功能变化对于全面了解
疾病进展和确定可能的治疗靶点。我的总体目标是
建议使用活的胰腺组织切片来探索β细胞在T1D发育过程中的功能,
具体地说,我将确定免疫细胞渗透在β细胞功能障碍和丢失中所起的作用。活体胰腺
组织切片是这些研究的理想选择,因为这些样本将胰岛保持在其自然微环境中
并保存现有的组织病理学,允许研究β细胞功能和免疫细胞
人口。我假设T1D进展早期的免疫失调会导致β功能障碍
细胞葡萄糖代谢途径主要由线粒体应激介导,导致MHC-I类
高表达并增加β细胞对免疫系统的可见性。为了验证这一假设,活体胰腺
从人类器官捐赠者组织产生的组织切片将被使用,并由由
T1D模型小鼠的胰腺组织。共聚焦显微镜技术将被用来确定
同时评估组织内的胰岛素炎和胰岛功能。其他功能评估
如灌流实验之后的胰岛素ELISA和基因表达将被用来观察
功能更详细。该提案的第一部分侧重于为确定
原位免疫细胞对β细胞功能的影响以获得对疾病时间表的更多控制,特别是
研究疾病的早期阶段,人类白细胞抗原匹配的T细胞替身将被引入来控制人类
胰腺组织切片,创造了一个与世隔绝的环境。疾病的发生和发展将被研究
进一步对NOD小鼠模型的脾细胞进行过继移植实验。进展到T1D
随着疾病的发展,将用活的胰腺组织切片进行监测。功能评估
免疫细胞研究将如上所述进行。我期待着拟议的
研究将确定免疫失调在β细胞功能障碍中所起的作用以及
β细胞功能障碍的机制起源。这将提供有关T1D如何发展的关键信息
并将指明可能的治疗目标,以阻止疾病的进展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mollie K Huber其他文献
Mollie K Huber的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mollie K Huber', 18)}}的其他基金
Investigating type 1 diabetes pathogenesis using the live pancreas tissue slice platform
使用活体胰腺组织切片平台研究 1 型糖尿病发病机制
- 批准号:
10388460 - 财政年份:2022
- 资助金额:
$ 4.19万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 4.19万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 4.19万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 4.19万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 4.19万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 4.19万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 4.19万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 4.19万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 4.19万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 4.19万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 4.19万 - 项目类别:














{{item.name}}会员




